Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 246 entries
Sorted by: Best Match Show Resources per page
Percolating hierarchical defect structures drive phase transformation in Ce1-x Gd x O2-x/2: a total scattering study.

IUCrJ

Scavini M, Coduri M, Allieta M, Masala P, Cappelli S, Oliva C, Brunelli M, Orsini F, Ferrero C.
PMID: 26306193
IUCrJ. 2015 Jul 30;2:511-22. doi: 10.1107/S2052252515011641. eCollection 2015 Sep 01.

A new hierarchical approach is presented for elucidating the structural disorder in Ce1-x Gd x O2-x/2 solid solutions on different scale lengths. The primary goal of this investigation is to shed light on the relations between the short-range and...

Cite
Scavini M, Coduri M, Allieta M, et al. Percolating hierarchical defect structures drive phase transformation in Ce1-x Gd x O2-x/2: a total scattering study. IUCrJ. 2015;2:511-22doi: 10.1107/S2052252515011641.
Scavini, M., Coduri, M., Allieta, M., Masala, P., Cappelli, S., Oliva, C., Brunelli, M., Orsini, F., & Ferrero, C. (2015). Percolating hierarchical defect structures drive phase transformation in Ce1-x Gd x O2-x/2: a total scattering study. IUCrJ, 2511-22. https://doi.org/10.1107/S2052252515011641
Scavini, Marco, et al. "Percolating hierarchical defect structures drive phase transformation in Ce1-x Gd x O2-x/2: a total scattering study." IUCrJ vol. 2 (2015): 511-22. doi: https://doi.org/10.1107/S2052252515011641
Scavini M, Coduri M, Allieta M, Masala P, Cappelli S, Oliva C, Brunelli M, Orsini F, Ferrero C. Percolating hierarchical defect structures drive phase transformation in Ce1-x Gd x O2-x/2: a total scattering study. IUCrJ. 2015 Jul 30;2:511-22. doi: 10.1107/S2052252515011641. eCollection 2015 Sep 01. PMID: 26306193; PMCID: PMC4547819.
Copy Download .nbib Format: NLM
Corrigendum to "APOA5 variants predispose hyperlipidemic patients to atherogenic dyslipidemia and subclinical atherosclerosis" [Atherosclerosis 240/1 (2015) 98-104].

Atherosclerosis

Guardiola M, Cofán M, de Castro-Orós I, Cenarro A, Plana N, Talmud PJ, Masana L, Ros E, Civeira F, Ribalta J.
PMID: 27180643
Atherosclerosis. 2016 Jul;250:190. doi: 10.1016/j.atherosclerosis.2016.05.008. Epub 2016 May 12.

No abstract available.

Cite
Guardiola M, Cofán M, de Castro-Orós I, et al. Corrigendum to "APOA5 variants predispose hyperlipidemic patients to atherogenic dyslipidemia and subclinical atherosclerosis" [Atherosclerosis 240/1 (2015) 98-104]. Atherosclerosis. 2016;250:190doi: 10.1016/j.atherosclerosis.2016.05.008.
Guardiola, M., Cofán, M., de Castro-Orós, I., Cenarro, A., Plana, N., Talmud, P. J., Masana, L., Ros, E., Civeira, F., & Ribalta, J. (2016). Corrigendum to "APOA5 variants predispose hyperlipidemic patients to atherogenic dyslipidemia and subclinical atherosclerosis" [Atherosclerosis 240/1 (2015) 98-104]. Atherosclerosis, 250190. https://doi.org/10.1016/j.atherosclerosis.2016.05.008
Guardiola, Montse, et al. "Corrigendum to "APOA5 variants predispose hyperlipidemic patients to atherogenic dyslipidemia and subclinical atherosclerosis" [Atherosclerosis 240/1 (2015) 98-104]." Atherosclerosis vol. 250 (2016): 190. doi: https://doi.org/10.1016/j.atherosclerosis.2016.05.008
Guardiola M, Cofán M, de Castro-Orós I, Cenarro A, Plana N, Talmud PJ, Masana L, Ros E, Civeira F, Ribalta J. Corrigendum to "APOA5 variants predispose hyperlipidemic patients to atherogenic dyslipidemia and subclinical atherosclerosis" [Atherosclerosis 240/1 (2015) 98-104]. Atherosclerosis. 2016 Jul;250:190. doi: 10.1016/j.atherosclerosis.2016.05.008. Epub 2016 May 12. PMID: 27180643.
Copy Download .nbib Format: NLM
Vilazodone for the Treatment of Depression: An Update.

Chonnam medical journal

Wang SM, Han C, Lee SJ, Patkar AA, Masand PS, Pae CU.
PMID: 27231672
Chonnam Med J. 2016 May;52(2):91-100. doi: 10.4068/cmj.2016.52.2.91. Epub 2016 May 20.

Vilazodone is a novel antidepressant having a selective serotonin (5-HT) reuptake inhibitor and 5-HT1A receptor partial agonist profile, so it has been regarded as a serotonin partial agonist-reuptake inhibitor (SPARI). We aimed to provide Vilazodone's clinical implications mainly by...

Cite
Wang SM, Han C, Lee SJ, et al. Vilazodone for the Treatment of Depression: An Update. Chonnam Med J. 2016;52(2):91-100doi: 10.4068/cmj.2016.52.2.91.
Wang, S. M., Han, C., Lee, S. J., Patkar, A. A., Masand, P. S., & Pae, C. U. (2016). Vilazodone for the Treatment of Depression: An Update. Chonnam medical journal, 52(2), 91-100. https://doi.org/10.4068/cmj.2016.52.2.91
Wang, Sheng-Min, et al. "Vilazodone for the Treatment of Depression: An Update." Chonnam medical journal vol. 52,2 (2016): 91-100. doi: https://doi.org/10.4068/cmj.2016.52.2.91
Wang SM, Han C, Lee SJ, Patkar AA, Masand PS, Pae CU. Vilazodone for the Treatment of Depression: An Update. Chonnam Med J. 2016 May;52(2):91-100. doi: 10.4068/cmj.2016.52.2.91. Epub 2016 May 20. PMID: 27231672; PMCID: PMC4880584.
Copy Download .nbib Format: NLM
Effects of milnacipran on neurocognition, pain, and fatigue in fibromyalgia: a 13-week, randomized, placebo-controlled, crossover trial.

The primary care companion for CNS disorders

Kim JL, Rele S, Marks DM, Masand PS, Yerramsetty P, Millet RA, Keefe RS, Patkar AA.
PMID: 24800123
Prim Care Companion CNS Disord. 2013;15(6). doi: 10.4088/PCC.13m01555. Epub 2014 Dec 26.

OBJECTIVE: To investigate whether milnacipran is safe and effective in improving cognitive function in patients with fibromyalgia.METHOD: Patients were randomly assigned to receive milnacipran or placebo for 6 weeks, followed by a 1-week washout and then crossover to the...

Cite
Kim JL, Rele S, Marks DM, et al. Effects of milnacipran on neurocognition, pain, and fatigue in fibromyalgia: a 13-week, randomized, placebo-controlled, crossover trial. Prim Care Companion CNS Disord. 2014;15(6)doi: 10.4088/PCC.13m01555.
Kim, J. L., Rele, S., Marks, D. M., Masand, P. S., Yerramsetty, P., Millet, R. A., Keefe, R. S., & Patkar, A. A. (2013). Effects of milnacipran on neurocognition, pain, and fatigue in fibromyalgia: a 13-week, randomized, placebo-controlled, crossover trial. The primary care companion for CNS disorders, 15(6), . https://doi.org/10.4088/PCC.13m01555
Kim, Jeong Lan, et al. "Effects of milnacipran on neurocognition, pain, and fatigue in fibromyalgia: a 13-week, randomized, placebo-controlled, crossover trial." The primary care companion for CNS disorders vol. 15,6 (2013). doi: https://doi.org/10.4088/PCC.13m01555
Kim JL, Rele S, Marks DM, Masand PS, Yerramsetty P, Millet RA, Keefe RS, Patkar AA. Effects of milnacipran on neurocognition, pain, and fatigue in fibromyalgia: a 13-week, randomized, placebo-controlled, crossover trial. Prim Care Companion CNS Disord. 2013;15(6). doi: 10.4088/PCC.13m01555. Epub 2014 Dec 26. PMID: 24800123; PMCID: PMC3977772.
Copy Download .nbib Format: NLM
Deep brain stimulation amplitude alters posture shift velocity in Parkinson's disease.

Cognitive neurodynamics

Krishnamurthi N, Mulligan S, Mahant P, Samanta J, Abbas JJ.
PMID: 24995048
Cogn Neurodyn. 2012 Aug;6(4):325-32. doi: 10.1007/s11571-012-9201-5. Epub 2012 Apr 12.

Deep brain stimulation (DBS) of the subthalamic nucleus (STN) is now widely used to alleviate symptoms of Parkinson's disease (PD). The specific aim of this study was to identify posture control measures that may be used to improve selection...

Cite
Krishnamurthi N, Mulligan S, Mahant P, et al. Deep brain stimulation amplitude alters posture shift velocity in Parkinson's disease. Cogn Neurodyn. 2012;6(4):325-32doi: 10.1007/s11571-012-9201-5.
Krishnamurthi, N., Mulligan, S., Mahant, P., Samanta, J., & Abbas, J. J. (2012). Deep brain stimulation amplitude alters posture shift velocity in Parkinson's disease. Cognitive neurodynamics, 6(4), 325-32. https://doi.org/10.1007/s11571-012-9201-5
Krishnamurthi, Narayanan, et al. "Deep brain stimulation amplitude alters posture shift velocity in Parkinson's disease." Cognitive neurodynamics vol. 6,4 (2012): 325-32. doi: https://doi.org/10.1007/s11571-012-9201-5
Krishnamurthi N, Mulligan S, Mahant P, Samanta J, Abbas JJ. Deep brain stimulation amplitude alters posture shift velocity in Parkinson's disease. Cogn Neurodyn. 2012 Aug;6(4):325-32. doi: 10.1007/s11571-012-9201-5. Epub 2012 Apr 12. PMID: 24995048; PMCID: PMC4079846.
Copy Download .nbib Format: NLM
Second Generation Antipsychotics in the Treatment of Major Depressive Disorder: An Update.

Chonnam medical journal

Wang SM, Han C, Lee SJ, Jun TY, Patkar AA, Masand PS, Pae CU.
PMID: 27689026
Chonnam Med J. 2016 Sep;52(3):159-72. doi: 10.4068/cmj.2016.52.3.159. Epub 2016 Sep 23.

Less than one third of patients who suffer from major depressive disorder (MDD) report remission following antidepressant treatments requiring more diverse treatment approaches. Augmentation of second generation antipsychotics (SGAs) has been increasingly recognized as an important treatment option. The...

Cite
Wang SM, Han C, Lee SJ, et al. Second Generation Antipsychotics in the Treatment of Major Depressive Disorder: An Update. Chonnam Med J. 2016;52(3):159-72doi: 10.4068/cmj.2016.52.3.159.
Wang, S. M., Han, C., Lee, S. J., Jun, T. Y., Patkar, A. A., Masand, P. S., & Pae, C. U. (2016). Second Generation Antipsychotics in the Treatment of Major Depressive Disorder: An Update. Chonnam medical journal, 52(3), 159-72. https://doi.org/10.4068/cmj.2016.52.3.159
Wang, Sheng-Min, et al. "Second Generation Antipsychotics in the Treatment of Major Depressive Disorder: An Update." Chonnam medical journal vol. 52,3 (2016): 159-72. doi: https://doi.org/10.4068/cmj.2016.52.3.159
Wang SM, Han C, Lee SJ, Jun TY, Patkar AA, Masand PS, Pae CU. Second Generation Antipsychotics in the Treatment of Major Depressive Disorder: An Update. Chonnam Med J. 2016 Sep;52(3):159-72. doi: 10.4068/cmj.2016.52.3.159. Epub 2016 Sep 23. PMID: 27689026; PMCID: PMC5040765.
Copy Download .nbib Format: NLM
Interactions Between Antibody-Coated Iron Micro-Particles and Leukemic Cells as seen by Electron Microscopy.

Leukemia & lymphoma

Bieva CJ, Mosselmans R, Brugghen FV, Kedar A, Erdos G, Fruhling J, Stryckmans P, Galand P.
PMID: 27457579
Leuk Lymphoma. 1991;6(1):75-81. doi: 10.3109/10428199109064882.

An electron microscopy study was performed to visualize the interactions between monoclonal antibodies (MoAbs) coated to ferromagnetic microparticles and leukemic cells. The properties of this specific reagent used for the efficient purging of residual leukemic cells from autografts before...

Cite
Bieva CJ, Mosselmans R, Brugghen FV, et al. Interactions Between Antibody-Coated Iron Micro-Particles and Leukemic Cells as seen by Electron Microscopy. Leuk Lymphoma. 1991;6(1):75-81doi: 10.3109/10428199109064882.
Bieva, C. J., Mosselmans, R., Brugghen, F. V., Kedar, A., Erdos, G., Fruhling, J., Stryckmans, P., & Galand, P. (1991). Interactions Between Antibody-Coated Iron Micro-Particles and Leukemic Cells as seen by Electron Microscopy. Leukemia & lymphoma, 6(1), 75-81. https://doi.org/10.3109/10428199109064882
Bieva, C J, et al. "Interactions Between Antibody-Coated Iron Micro-Particles and Leukemic Cells as seen by Electron Microscopy." Leukemia & lymphoma vol. 6,1 (1991): 75-81. doi: https://doi.org/10.3109/10428199109064882
Bieva CJ, Mosselmans R, Brugghen FV, Kedar A, Erdos G, Fruhling J, Stryckmans P, Galand P. Interactions Between Antibody-Coated Iron Micro-Particles and Leukemic Cells as seen by Electron Microscopy. Leuk Lymphoma. 1991;6(1):75-81. doi: 10.3109/10428199109064882. PMID: 27457579.
Copy Download .nbib Format: NLM
Utility of gastric lavage in vigorous neonates delivered with meconium stained liquor: a randomized controlled trial.

International journal of pediatrics

Garg J, Masand R, Tomar BS.
PMID: 24868210
Int J Pediatr. 2014;2014:204807. doi: 10.1155/2014/204807. Epub 2014 Apr 24.

Objective. To determine the incidence of feed intolerance in vigorous babies with meconium stained liquor (MSL) who received prophylactic gastric lavage as compared to those who were not subjected to this procedure. Design. Randomized controlled trial. Setting. Tertiary care...

Cite
Garg J, Masand R, Tomar BS. Utility of gastric lavage in vigorous neonates delivered with meconium stained liquor: a randomized controlled trial. Int J Pediatr. 2014;2014:204807doi: 10.1155/2014/204807.
Garg, J., Masand, R., & Tomar, B. S. (2014). Utility of gastric lavage in vigorous neonates delivered with meconium stained liquor: a randomized controlled trial. International journal of pediatrics, 2014204807. https://doi.org/10.1155/2014/204807
Garg, Jatin, et al. "Utility of gastric lavage in vigorous neonates delivered with meconium stained liquor: a randomized controlled trial." International journal of pediatrics vol. 2014 (2014): 204807. doi: https://doi.org/10.1155/2014/204807
Garg J, Masand R, Tomar BS. Utility of gastric lavage in vigorous neonates delivered with meconium stained liquor: a randomized controlled trial. Int J Pediatr. 2014;2014:204807. doi: 10.1155/2014/204807. Epub 2014 Apr 24. PMID: 24868210; PMCID: PMC4020371.
Copy Download .nbib Format: NLM
Gabapentin in the Treatment of Aggression Associated With Conduct Disorder.

Primary care companion to the Journal of clinical psychiatry

Gupta S, Frank BL, Masand PS.
PMID: 15014586
Prim Care Companion J Clin Psychiatry. 2000 Apr;2(2):60-61. doi: 10.4088/pcc.v02n0208c.

No abstract available.

Cite
Gupta S, Frank BL, Masand PS. Gabapentin in the Treatment of Aggression Associated With Conduct Disorder. Prim Care Companion J Clin Psychiatry. 2000;2(2):60-61doi: 10.4088/pcc.v02n0208c.
Gupta, S., Frank, B. L., & Masand, P. S. (2000). Gabapentin in the Treatment of Aggression Associated With Conduct Disorder. Primary care companion to the Journal of clinical psychiatry, 2(2), 60-61. https://doi.org/10.4088/pcc.v02n0208c
Gupta, Sanjay, et al. "Gabapentin in the Treatment of Aggression Associated With Conduct Disorder." Primary care companion to the Journal of clinical psychiatry vol. 2,2 (2000): 60-61. doi: https://doi.org/10.4088/pcc.v02n0208c
Gupta S, Frank BL, Masand PS. Gabapentin in the Treatment of Aggression Associated With Conduct Disorder. Prim Care Companion J Clin Psychiatry. 2000 Apr;2(2):60-61. doi: 10.4088/pcc.v02n0208c. PMID: 15014586; PMCID: PMC181210.
Copy Download .nbib Format: NLM
Novel Antipsychotics in the Treatment of Behavioral Disturbances and Psychoses Associated With Neurodegenerative Disorders.

Primary care companion to the Journal of clinical psychiatry

Masand PS.
PMID: 15014653
Prim Care Companion J Clin Psychiatry. 2000 Jun;2(3):80-88. doi: 10.4088/pcc.v02n0302.

Behavioral disturbances and psychosis are common features of neurodegenerative disorders and may be drug induced, intrinsic to the underlying pathology, or both. These disturbances, including psychotic and mood symptoms, apathy, aggression and other behavioral symptoms, and superimposed delirium, cause...

Cite
Masand PS. Novel Antipsychotics in the Treatment of Behavioral Disturbances and Psychoses Associated With Neurodegenerative Disorders. Prim Care Companion J Clin Psychiatry. 2000;2(3):80-88doi: 10.4088/pcc.v02n0302.
Masand, P. S. (2000). Novel Antipsychotics in the Treatment of Behavioral Disturbances and Psychoses Associated With Neurodegenerative Disorders. Primary care companion to the Journal of clinical psychiatry, 2(3), 80-88. https://doi.org/10.4088/pcc.v02n0302
Masand, Prakash S.. "Novel Antipsychotics in the Treatment of Behavioral Disturbances and Psychoses Associated With Neurodegenerative Disorders." Primary care companion to the Journal of clinical psychiatry vol. 2,3 (2000): 80-88. doi: https://doi.org/10.4088/pcc.v02n0302
Masand PS. Novel Antipsychotics in the Treatment of Behavioral Disturbances and Psychoses Associated With Neurodegenerative Disorders. Prim Care Companion J Clin Psychiatry. 2000 Jun;2(3):80-88. doi: 10.4088/pcc.v02n0302. PMID: 15014653; PMCID: PMC181113.
Copy Download .nbib Format: NLM
Acute and recurring pericarditis: More colchicine, less corticosteroids.

World journal of cardiology

Farand P, Bonenfant F, Belley-Côté EP, Tzouannis N.
PMID: 21191540
World J Cardiol. 2010 Dec 26;2(12):403-7. doi: 10.4330/wjc.v2.i12.403.

Acute and recurring pericarditis are frequently encountered clinical entities. Given that severe complications such as tamponade and constrictive pericarditis occur rarely, the majority of patients suffering from acute pericarditis will have a benign clinical course. However, pericarditis recurrence, with...

Cite
Farand P, Bonenfant F, Belley-Côté EP, et al. Acute and recurring pericarditis: More colchicine, less corticosteroids. World J Cardiol. 2010;2(12):403-7doi: 10.4330/wjc.v2.i12.403.
Farand, P., Bonenfant, F., Belley-Côté, E. P., & Tzouannis, N. (2010). Acute and recurring pericarditis: More colchicine, less corticosteroids. World journal of cardiology, 2(12), 403-7. https://doi.org/10.4330/wjc.v2.i12.403
Farand, Paul, et al. "Acute and recurring pericarditis: More colchicine, less corticosteroids." World journal of cardiology vol. 2,12 (2010): 403-7. doi: https://doi.org/10.4330/wjc.v2.i12.403
Farand P, Bonenfant F, Belley-Côté EP, Tzouannis N. Acute and recurring pericarditis: More colchicine, less corticosteroids. World J Cardiol. 2010 Dec 26;2(12):403-7. doi: 10.4330/wjc.v2.i12.403. PMID: 21191540; PMCID: PMC3011134.
Copy Download .nbib Format: NLM
Review of olanzapine in the management of bipolar disorders.

Neuropsychiatric disease and treatment

Narasimhan M, Bruce TO, Masand P.
PMID: 19300587
Neuropsychiatr Dis Treat. 2007;3(5):579-87.

Olanzapine is an atypical antipsychotic currently with indications for the treatment of schizophrenia, acute mania and the prevention of relapse in bipolar disorder. A growing body of clinical evidence supports these indications. Acute mania trials have demonstrated superior efficacy...

Cite
Narasimhan M, Bruce TO, Masand P. Review of olanzapine in the management of bipolar disorders. Neuropsychiatr Dis Treat. 2007;3(5):579-87
Narasimhan, M., Bruce, T. O., & Masand, P. (2007). Review of olanzapine in the management of bipolar disorders. Neuropsychiatric disease and treatment, 3(5), 579-87.
Narasimhan, Meera, et al. "Review of olanzapine in the management of bipolar disorders." Neuropsychiatric disease and treatment vol. 3,5 (2007): 579-87.
Narasimhan M, Bruce TO, Masand P. Review of olanzapine in the management of bipolar disorders. Neuropsychiatr Dis Treat. 2007;3(5):579-87. PMID: 19300587; PMCID: PMC2656294.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 246 entries